LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Kronos Bio

Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.

  • Norbert Bischofberger, PhD President & Chief Executive Officer
  • Angela Koehler, PhD Scientific Founder; Assistant Professor, Koch Institute for Integrative Cancer Research (MIT)
  • Christopher Wilfong Chief Operating Officer